April 22, 2025

Dear Congressman Taylor,

I write to you today on behalf of concerned citizens across Ohio, compelled by a recent and deeply unsettling report published by the Ethics and Public Policy Center—the largest study to date on the outcomes of chemical abortions. This analysis, covering over 865,000 cases between 2017 and 2023, uncovers a profoundly disturbing reality: nearly 11% of women who used abortion drugs experienced serious complications, including hemorrhaging, sepsis, infection, and tragically, death in some cases.

These findings directly contradict the FDA's long-standing claims that adverse effects from these drugs occur in only 0.5% of cases. In truth, the actual complication rate is more than 20 times higher than previously reported. This is not a minor discrepancy—it is a catastrophic failure of oversight that endangers countless women.

Several points demand urgent attention:

- **Chemical abortion drugs are not as safe as advertised**. The narrative that these pills are no more risky than common medications like Tylenol is misleading and dangerous.
- **The move toward mail-order distribution without in-person medical evaluation or follow-up care puts women—and especially young girls—at extreme risk.**
- **The FDA has pushed forward with deregulation despite relying on outdated or incomplete data, and this raises pressing questions about what other risks may be going unreported or intentionally obscured.**

Despite these risks, chemical abortions now account for most abortions nationwide. The abortion industry and its pharmaceutical allies continue to profit heavily, even as evidence of harm mounts. There is a clear and troubling prioritization of profit over women's health and safety.

This issue has escalated into a public health crisis. Women deserve the full truth, rigorous safety standards, and protection from dangerous, profit-driven practices. That is why we respectfully urge you to act by calling for congressional hearings to thoroughly investigate the FDA's handling of these drugs, including its approval process, its mail-order policies, and its failure to require comprehensive adverse event reporting.

Congressman Taylor, your voice is needed to expose these dangers and demand accountability. We are grateful for your dedication to life and liberty, and we trust you will approach this matter with the urgency and integrity it requires.

Thank you for your leadership and your commitment to protecting the most vulnerable among us.

Sincerely,